<DOC>
	<DOCNO>NCT02353026</DOCNO>
	<brief_summary>This Phase One study determine safety , tolerability , maximum tolerate dose intravenous artesunate patient solid tumor . A rapid dose escalation design use , single patient enrol escalate dose level grade 2 high toxicity occur cycle 1 . Enrollment continue use 3 6 patient dose level dose reach 2 patient 6 experience treatment-related toxicity .</brief_summary>
	<brief_title>Phase I Study Intravenous Artesunate Solid Tumors</brief_title>
	<detailed_description>A rapid dose escalation design use , single patient enrol dose level grade &gt; /= 2 treatment-related toxicity occur cycle 1 ; enrollment proceed use classic 3+ 3 dose escalation design . If toxicity grade 2 , enrollment continue dose level . If toxicity grade 3 4 , enrollment continue one dose level dose . Dose escalation 3+3 design continue &gt; /= 2 patient 6 experience treatment-related dose-limiting toxicity . Then , maximum tolerate dose recommended Phase II dose intravenous artesunate one dose level level toxicity occur .</detailed_description>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>At least one measurable lesion RECIST criterion Willing undergo pharmacogenetic testing Over age 18 year able provide inform consent No standard care therapy available proven overall survival benefit Adequate kidney , liver , bone marrow function Life expectancy great 3 month ECOG performance status less equal 2 Chemotherapy surgery within 4 week treatment start Radiation treatment within 3 week prior treatment start Untreated brain metastasis neurologically unstable CNS metastases Any severe uncontrolled medical condition condition could affect participation study include : unstable angina , serious uncontrolled cardiac arrhythmia , uncontrolled infection , myocardial infarction &lt; /= 6 month prior study entry Previous diagnosis alpha betathalassemia Patients medication herbal therapy know inhibit CYP2A6 , UGT1A9 , UGT2B7 Female patient pregnant breast feeding , adult patient reproductive potential unwilling refrain conceive child study treatment Patients unwilling unable comply protocol , provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>